𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population

✍ Scribed by David J. Kaplan; Stephen A. Boorjian; Karen Ruth; Brian L. Egleston; David Y. T. Chen; Rosalia Viterbo; Robert G. Uzzo; Mark K. Buyyounouski; Susan Raysor; Veda N. Giri

Book ID
109056074
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
181 KB
Volume
105
Category
Article
ISSN
1464-4096

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Trichomonosis and subsequent risk of pro
Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial
✍ Siobhan Sutcliffe; John F. Alderete; Cathee Till; Phyllis J. Goodman; Ann W. Hsi πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 French βš– 94 KB πŸ‘ 1 views

## Abstract We previously observed a positive association between a history of trichomonosis, a sexually transmitted infection caused by the protozoan, __Trichomonas vaginalis__, and prostate cancer risk in the Health Professionals Follow‐up Study. To determine the reproducibility of this finding,

Age specific risks of familial prostate
Age specific risks of familial prostate carcinoma : A basis for screening recommendations in high risk populations
✍ Henrik GrΓΆnberg; Fredrik Wiklund; Jan-Erik Damber πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 113 KB πŸ‘ 2 views

A positive family history is one of the strongest known risk factors for prostate carcinoma in addition to age and race. In this article, the authors present age specific risks for developing prostate carcinoma in families with an aggregation of prostate carcinoma. ## METHODS. Data from a populati

Serum estrogen levels and prostate cance
Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case–control study
✍ Song Yao; Cathee Till; Alan R. Kristal; Phyllis J. Goodman; Ann W. Hsing; Cather πŸ“‚ Article πŸ“… 2011 πŸ› Springer Netherlands 🌐 English βš– 190 KB

## Objective Finasteride reduces prostate cancer risk by blocking the conversion of testosterone to dihydrotestosterone. However, whether finasteride affects estrogens levels or change in estrogens affects prostate cancer risk is unknown. ## Methods These questions were investigated in a case–con